Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

Abstract Background About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, hav...

詳細記述

書誌詳細

主要な著者:	Relinde I. Y. Lieverse, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois, Philippe Lambin
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2020-06-01
シリーズ:	BMC Cancer
主題:	Immunotherapy L19-IL2 Anti-PD-L1 Anti-PD-1 Radiotherapy SABR
オンライン･アクセス:	http://link.springer.com/article/10.1186/s12885-020-07055-1
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!